BAR HARBOR, Maine and
MOUNTAIN VIEW, Calif.,
May 10,
2024 /PRNewswire/ -- The Jackson Laboratory (JAX), an
independent, nonprofit biomedical research organization, and
AbTherx, an innovator in biotechnology, announced a strategic
partnership to develop and commercialize cutting-edge tools to
expedite antibody discovery and derisk the development of vital new
therapies. This collaboration will include co-development
activities and leverages JAX's extensive experience in model
research and AbTherx's Atlas™ Mouse platform to
address critical challenges facing drug developers of all
sizes.
The Atlas™ Mouse technologies are engineered to
leverage in vivo antibody selection and maturation processes for
the creation of human antibodies and are specifically designed to
overcome the limitations of historical antibody discovery
technologies by offering enhanced speed, diversity, developability,
and affinity. Such traits are essential for developing viable lead
candidates more swiftly than traditional methods currently
allow.
JAX will also become the exclusive distributor of select
Atlas™ Mouse models, including AbTherx's Full Human
Diversity Mouse for monoclonal antibody development as well as the
Binary Fixed Light Chain Mouse for bispecific and multispecific
antibody development. JAX and AbTherx are additionally exploring
opportunities to develop and distribute future models to expand on
this existing suite of innovative tools.
"By combining JAX's expertise in high-quality mouse models with
the innovative capabilities of our Atlas™ Mouse
platform, we are setting new industry standards," said Justin Mika, CEO of AbTherx. "This collaboration
not only enhances our ability to create additional impactful
technologies but also ensures that these advancements are within
reach of researchers and developers globally, fostering a new era
of medical innovation."
"Providing access to high-quality research tools is paramount at
The Jackson Laboratory, and we are thrilled to extend our
capabilities with innovative models that are pivotal for the
creation of new therapeutics," said Mitchell Kennedy, Executive Vice President of
The Jackson Laboratory and President of JAX Mice, Clinical &
Research Services. "Our partnership with AbTherx is a natural
synergy, combining our decades of expertise in mouse model
development with their deep knowledge in antibody discovery.
Together, we are not only enhancing the tools available to
researchers but also accelerating the pace at which impactful
treatments can reach patients worldwide."
An early access program is set to launch in the second half of
the year, during which time drug developers are invited to test and
evaluate these groundbreaking platforms. For more details or to
participate in the early access program, please contact JAX at
micetech@jax.org.
About The Jackson Laboratory
The Jackson Laboratory is an independent, nonprofit biomedical
research institution with a National Cancer Institute-designated
Cancer Center and nearly 3,000 employees in locations across
the United States, Japan, and China. Its mission is to discover precise
genomic solutions for disease and empower the global biomedical
community in the shared quest to improve human health. For more
information, please visit www.jax.org.
About AbTherx
AbTherx is advancing medicine with revolutionary technologies
that accelerate and enable therapeutic antibody discovery. Through
an exclusive partnership with Gilead Sciences, AbTherx has released
Atlas™ Mice, a suite of novel transgenic technologies
designed for unmatched performance and FTO. For over 20 years,
AbTherx's passionate, innovative, and collaborative team has pushed
the boundaries of antibody discovery technologies, leading to over
1,000 successful antibody discovery campaigns and 13 marketed
therapeutics. AbTherx's industry-leading team creates
transformative solutions to overcome the most demanding challenges
in delivering innovative medicines. Committed to making its
technologies accessible to all, AbTherx offers flexible partnering
models that meet the needs of drug developers of all sizes. For
more information, please visit www.abtherx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-jackson-laboratory-and-abtherx-announce-partnership-to-enhance-therapeutic-antibody-discovery-302142742.html
SOURCE The Jackson Laboratory